MariMed Inc.
OTCPKShort interest % of float, cost to borrow, utilization, and put/call ratio for MRMD are part of the ORTEX premium tier. Sign up to read the live numbers alongside the analysis.
Snapshot as of 14 May 2026
MariMed heads into its May 14 earnings report as one of the OTC cannabis sector's quieter short stories — but the stock's sharp one-month rally makes the print a genuine test of momentum. The lending market tells a…
MRMD just reported Q1 2026 results after the close on May 13, beating the revenue consensus estimate of $38.75M with $39.48M in sales. The earnings call follows on May 14. That puts the stock at an interesting juncture…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MRMD — free to start on ORTEX.
Sign up for free →Open MRMD on ORTEX